Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer

Resistance to chemotherapy remains a critical barrier to effective cancer treatment. Although cisplatin is one of the most commonly used chemotherapeutic agents in the treatment of non-small cell lung cancer (NSCLC), mechanisms of resistance to this drug are not fully understood. Here, we report a n...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncogene
Hoofdauteurs: Kim, In-Kyu, McCutcheon, Justine N., Rao, Guanhua, Liu, Stephen V., Pommier, Yves, Skrzypski, Marcin, Zhang, Yu-Wen, Giaccone, Giuseppe
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2018
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8274951/
https://ncbi.nlm.nih.gov/pubmed/30093630
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41388-018-0429-3
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items